The case for Dutasteride ONCE A WEEK vs daily Fin/Dut as cost effective light approach
    4/28/2021

    From the encyclopedia
    Dutasteride β†’

    Heavy duty finasteride that comes with higher risks

    Finasteride β†’

    Frontline, gold standard treatment for combatting androgenic alopecia

    Minoxidil β†’

    An essential vasodilator with some anti-androgenic effects

    At a glance
    In this hair loss treatment regimen post, the primary subjects mentioned are
    πŸ’Š Dutasteride (oral) 0.5mg 1x weekly
    πŸ’Š Finasteride (oral) 1mg varies
    πŸ’§ Minoxidil (topical)
    πŸ’§ Dermarolling (topical)
    the tone is 😐 neutral.

    Other terms

    Dutasteride once a week may be a cost-effective alternative to daily finasteride for reducing DHT levels, with potential benefits for those seeking a lighter approach to hair loss treatment. Some users combine dutasteride with finasteride, minoxidil, and dermarolling for improved results.
    View this post in the Community β†’

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Experimental and Early Investigational Drugs for Androgenetic Alopecia

      research Experimental and early investigational drugs for androgenetic alopecia

      11 citations , July 2017 in “Expert Opinion on Investigational Drugs”
      This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.
      Finasteride in Androgenetic Alopecia in Men

      research Finasteride in androgenetic alopecia in men

      June 2007 in “Advances in Dermatology and Allergology/PostΔ™py Dermatologii i Alergologii”
      This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.
      The Inflammatory Component of Androgenetic Alopecia

      research The inflammatory component of androgenetic alopecia

      3 citations , November 2021 in “Journal of The American Academy of Dermatology”
      This article discusses hormonal mechanisms underlying androgenetic alopecia but does not report any new findings; it reviews the roles of dihydrotestosterone and available FDA-approved treatments.
      Updates in Treatment for Androgenetic Alopecia

      research Updates in Treatment for Androgenetic Alopecia

      January 2025 in “Annals of Dermatology”
      This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.